Site Map

• mBC Home

• Efficacy

  Efficacy

  • Efficacy Across Trials
  • KISQALI + AI in Postmenopausal Patients
  • KISQALI + Fulvestrant in Postmenopausal Patients
  • KISQALI + AI in Premenopausal Patients
  • Aggressive & Visceral Disease

• Health-Related QOL

• PK/PD Data

• Safety

  Safety

  • KISQALI + Letrozole in Postmenopausal Patients
  • KISQALI + Fulvestrant in Postmenopausal Patients
  • KISQALI + AI in Premenopausal Patients

• Start & Stay on KISQALI

• Assessments & Dosing

  Assessments & Dosing

  • Scheduled Assessments
  • Dosing
  • Dose Adjustments
  • Dose Reduction Data

• Novartis Patient Support

• Medical Expert Videos & Resources

  Medical Expert Videos & Resources

  • Medical Expert Videos
  • Resources

• eBC Home

• Risk of Recurrence

  Risk of Recurrence

  • Risk by Nodal Status and Stage
  • Evaluating Risk

• Efficacy

  Efficacy

  • NATALEE Trial
  • Invasive Disease-Free Survival
  • Distant Disease-Free Survival
  • Invasive Disease-Free Survival: Subgroups

• Health-Related QOL

• Safety

• Patient Profiles

  Patient Profiles

  • Profile Summary
  • Stage II (T2N1)
  • Stage II (T2N0)
  • Stage III (T2N2)

• Start & Stay on KISQALI

• Assessments & Dosing

  Assessments & Dosing

  • Scheduled Assessments
  • Dosing
  • Dose Adjustments

• Novartis Patient Support

• Medical Expert Videos & Resources

  Medical Expert Videos & Resources

  • Medical Expert Videos
  • Resources

• Explore KISQALI for eBC

• Explore KISQALI for mBC